Literature DB >> 11774239

Expression of heavy subunit of gamma-glutamylcysteine synthetase (gamma-GCSh) in human colorectal carcinoma.

Shigeru Tatebe1, Hitoshi Unate, Frank A Sinicrope, Takashi Sakatani, Kenji Sugamura, Masato Makino, Hisao Ito, Niramol Savaraj, Nobuaki Kaibara, M Tien Kuo.   

Abstract

Gamma-glutamylcysteine synthetase (gamma-GCS) is a heterodimer consisting of heavy (gamma-GCSh) and light (gamma-GCSl) subunits. gamma-GCS catalyzes the rate-limiting de novo biosynthesis of glutathione (GSH), an abundant physiological antioxidant that plays important roles for regulating oxidative stress. Expression of gamma-GCSh and gamma-GCSl are sensitive to oxidative stress. To investigate whether expression of gamma-GCS is correlated with tumor progression, we used immunohistochemical approaches to examine 16 human colorectal adenomas and resected 57 carcinomas from untreated patients. In adjacent normal colorectal epithelium, levels of gamma-GCSh expression were low. Strong cytoplasmic staining for gamma-GCSh was detected in 3 (18.8%) adenoma and 48 (84.2%) carcinomas. The frequency of gamma-GCSh expression in carcinoma was significantly higher than in adenoma (p<0.0001). We used RNase protation assay and Western blot to determine levels of gamma-GCSh mRNA and protein from 10 pairs of matched carcinomas with adjacent normal controls. Elevated expression of both gamma-GCSh mRNA and protein were found in 6 cases, suggesting that transcriptional and/or posttranscriptional regulation play an important role in the upregulation of gamma-GCS during colorectal carcinogenesis. We also examined the expression of another redox-regulated gene, multidrug resistance protein 1 (MRP1). Strong staining for MRP1 was detected in 1 (6.3%) adenoma and 40 (70.2%) carcinomas. The frequency of MRP1 expression in carcinoma was significantly higher than in adenoma ( p<0.0001). Nuclear p53 expression was detected in 30 (52.6%) of carcinomas. There is a significant correlation between gamma-GCSh and MRP1 expression (p=0.013) but not between gamma-GCSh and p53. Since gamma-GCS is a sensor of oxidative stress, these results are consistent with the notion that oxidative stress is associated with colorectal tumor progression. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11774239     DOI: 10.1002/ijc.1574

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  High expression of GCLC is associated with malignant melanoma of low oxidative phenotype and predicts a better prognosis.

Authors:  Dimitrios Mougiakakos; Riki Okita; Takashi Ando; Christoph Dürr; Jules Gadiot; Jiro Ichikawa; Robert Zeiser; Christian Blank; C Christian Johansson; Rolf Kiessling
Journal:  J Mol Med (Berl)       Date:  2012-01-17       Impact factor: 4.599

2.  Role of glutathione in the regulation of Cisplatin resistance in cancer chemotherapy.

Authors:  Helen H W Chen; Macus Tien Kuo
Journal:  Met Based Drugs       Date:  2010-09-14

Review 3.  Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities.

Authors:  Macus Tien Kuo
Journal:  Antioxid Redox Signal       Date:  2009-01       Impact factor: 8.401

4.  Elevated GSH level increases cadmium resistance through down-regulation of Sp1-dependent expression of the cadmium transporter ZIP8.

Authors:  Isamu Aiba; Anwar Hossain; Macus Tien Kuo
Journal:  Mol Pharmacol       Date:  2008-06-12       Impact factor: 4.436

5.  Non-canonical Glutamate-Cysteine Ligase Activity Protects against Ferroptosis.

Authors:  Yun Pyo Kang; Andrea Mockabee-Macias; Chang Jiang; Aimee Falzone; Nicolas Prieto-Farigua; Everett Stone; Isaac S Harris; Gina M DeNicola
Journal:  Cell Metab       Date:  2020-12-22       Impact factor: 31.373

6.  Exploration of the Proteomic Landscape of Small Extracellular Vesicles in Serum as Biomarkers for Early Detection of Colorectal Neoplasia.

Authors:  Li-Chun Chang; Yi-Chiung Hsu; Han-Mo Chiu; Koji Ueda; Ming-Shiang Wu; Chiun-How Kao; Tang-Long Shen
Journal:  Front Oncol       Date:  2021-09-13       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.